Our data also suggest that CSK low CRPCs might respond to inhibition of pathways and cellular processes set into motion by loss of ETS2 and ZFHX3 function, two tumor suppressors specifically involved in the transition to CRPC [25], although regimens to do so remain to be discovered. The gene discussed is ETS2; the disease is neoplasm.